These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 24995482)

  • 1. No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation.
    Capobianco M; di Sapio A; Malentacchi M; Malucchi S; Matta M; Sperli F; Bertolotto A
    Eur J Neurol; 2015 Mar; 22(3):585-7. PubMed ID: 24995482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relapses in patients treated with fingolimod after previous exposure to natalizumab.
    Comi G; Gold R; Dahlke F; Sinha A; von Rosenstiel P; Tomic D; Kappos L
    Mult Scler; 2015 May; 21(6):786-90. PubMed ID: 25257618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report.
    Patti F; Leone C; Zappia M
    BMC Neurol; 2015 Dec; 15():252. PubMed ID: 26643473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment.
    Vollmer BL; Nair K; Sillau S; Corboy JR; Vollmer T; Alvarez E
    Ann Clin Transl Neurol; 2020 Sep; 7(9):1466-1476. PubMed ID: 32767538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
    Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
    Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
    Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching from natalizumab to fingolimod: an observational study.
    Sempere AP; Martín-Medina P; Berenguer-Ruiz L; Pérez-Carmona N; Sanchez-Perez R; Polache-Vengud J; Feliu-Rey E
    Acta Neurol Scand; 2013 Aug; 128(2):e6-e10. PubMed ID: 23336398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Natalizumab and Fingolimod on Clinical, Cognitive, and Magnetic Resonance Imaging Measures in Multiple Sclerosis.
    Preziosa P; Rocca MA; Riccitelli GC; Moiola L; Storelli L; Rodegher M; Comi G; Signori A; Falini A; Filippi M
    Neurotherapeutics; 2020 Jan; 17(1):208-217. PubMed ID: 31452082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Fingolimod and Natalizumab on Brain T1-/T2-Weighted and Magnetization Transfer Ratios: a 2-Year Study.
    Preziosa P; Storelli L; Meani A; Moiola L; Rodegher M; Filippi M; Rocca MA
    Neurotherapeutics; 2021 Apr; 18(2):878-888. PubMed ID: 33483938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients.
    Leurs CE; van Kempen ZL; Dekker I; Balk LJ; Wattjes MP; Rispens T; Uitdehaag BM; Killestein J
    Mult Scler; 2018 Oct; 24(11):1453-1460. PubMed ID: 28823223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
    Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rozsa C; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simo M; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H;
    Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-minimization analysis of alemtuzumab compared to fingolimod and natalizumab for the treatment of active relapsing-remitting multiple sclerosis in the Netherlands.
    Piena MA; Heisen M; Wormhoudt LW; Wingerden JV; Frequin STFM; Uitdehaag BMJ
    J Med Econ; 2018 Oct; 21(10):968-976. PubMed ID: 29911917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation.
    Mustonen T; Rauma I; Hartikainen P; Krüger J; Niiranen M; Selander T; Simula S; Remes AM; Kuusisto H
    Mult Scler Relat Disord; 2020 Feb; 38():101498. PubMed ID: 31864192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Switching therapy from natalizumab to fingolimod: reduction of the washout time?].
    Sánchez-Gundín J; Flor García A; Martí Gil C; Gómez Romero L
    Farm Hosp; 2015 Sep; 39(5):314-5. PubMed ID: 26546944
    [No Abstract]   [Full Text] [Related]  

  • 15. Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM.
    Voloshyna N; Havrdová E; Hutchinson M; Nehrych T; You X; Belachew S; Hotermans C; Paes D
    Eur J Neurol; 2015 Mar; 22(3):570-7. PubMed ID: 25511792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A longitudinal real-life comparison study of natalizumab and fingolimod.
    Lanzillo R; Carotenuto A; Moccia M; Saccà F; Russo CV; Massarelli M; De Rosa A; Brescia Morra V
    Acta Neurol Scand; 2017 Sep; 136(3):217-222. PubMed ID: 27976804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study.
    Zecca C; Merlini A; Disanto G; Rodegher M; Panicari L; Romeo MAL; Candrian U; Messina MJ; Pravatà E; Moiola L; Stefanin C; Ghezzi A; Perrone P; Patti F; Comi G; Gobbi C; Martinelli V
    Mult Scler; 2018 Feb; 24(2):167-174. PubMed ID: 28273776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of disability progression in fingolimod-treated patients.
    Lattanzi S; Danni M; Cerqua R; Taffi R; Provinciali L; Silvestrini M
    J Neurol Sci; 2015 Nov; 358(1-2):432-4. PubMed ID: 26362335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings.
    Rinaldi F; Seppi D; Calabrese M; Perini P; Gallo P
    Mult Scler; 2012 Nov; 18(11):1640-3. PubMed ID: 23100526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-line therapy with fingolimod for relapsing-remitting multiple sclerosis in clinical practice: the effect of previous exposure to natalizumab.
    Bianco A; Patanella AK; Nociti V; Marti A; Frisullo G; Plantone D; De Fino C; Fetta A; Batocchi AP; Rossini PM; Mirabella M
    Eur Neurol; 2015; 73(1-2):57-65. PubMed ID: 25402749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.